Table 5. Adjusted direct nominal medical costs during the follow-up period overall, by line of therapy.
| 2L, all regimens (n = 2927) | 3L, all regimens (n = 1085) | |
|---|---|---|
| Total cost, US$ | ||
| During follow-up, n | 2927 | 1085 |
| Mean (SD) | 77,173.5 (59,643.2) | 79,118.0 (60,657.0) |
| Median (Q1, Q3) | 62,848.0 (36,286.3, 99,202.7) | 62,576.3 (36,614.1, 105,864.8) |
| During index treatment, n | 2927 | 1085 |
| Mean (SD) | 33,210.1 (25,559.1) | 31,414.6 (26,109.8) |
| Median (Q1, Q3) | 28,056.8 (15,629.8, 44,143.5) | 25,761.5 (14,334.8, 40,894.3) |
| During 3L (only for 2L cohort), n | 2068 | |
| Mean (SD) | 28,020.9 (24,860.0) | |
| Median (Q1, Q3) | 22,596.8 (12,075.8, 36,635.1) | |
| Inpatient costs, US$ | ||
| During follow-up, n | 2833 | 1057 |
| Mean (SD) | 64,547.1 (54,326.9) | 66,798.9 (56,591.0) |
| Median (Q1, Q3) | 50,810.4 (25,646.3, 86,348.7) | 51,174.6 (26,944.8, 89,461.3) |
| During index treatment, n | 2757 | 1020 |
| Mean (SD) | 28,354.9 (23,089.3) | 26,965.7 (23,239.4) |
| Median (Q1, Q3) | 22,590.6 (11,798.3, 39,229.7) | 21,550.5 (11,562.8, 34,950.9) |
| During 3L (only for 2L cohort), n | 1884 | |
| Mean (SD) | 24,734.7 (21,526.9) | |
| Median (Q1, Q3) | 19,642.5 (10,404.5, 32,522.0) | |
| Outpatient costs, US$ | ||
| During follow-up, n | 2842 | 1053 |
| Mean (SD) | 15,139.0 (22,040.1) | 14,469.8 (20,110.9) |
| Median (Q1, Q3) | 8487.7 (3818.9, 18,215.0) | 7881.5 (3321.7, 16,929.8) |
| During index treatment, n | 2441 | 921 |
| Mean (SD) | 7796.6 (11,019.8) | 7144.2 (11,213.9) |
| Median (Q1, Q3) | 4151.3 (1324.2, 10,112.2) | 3580.5 (1250.5, 8517.5) |
| During 3L (only for 2L cohort), n | 1635 | |
| Mean (SD) | 6940.1 (13,076.5) | |
| Median (Q1, Q3) | 3286.0 (1119.7, 8020.7) | |
| Total cost of end-of-life care (1 month prior to death), US$ | ||
| n | 918 | 419 |
| Mean (SD) | 12,742.6 (9116.5) | 13,195.7 (9282.5) |
| Median (Q1, Q3) | 10,211.7 (7179.8, 16,225.7) | 10,848.8 (7368.0, 16,449.7) |
2L: Second-line; 3L: Third-line; Q: Quartile; SD: Standard deviation.